According to the Health Promotion Administration (HPA) of the MOHW, there were 111,684 registered cancer cases in 2017; and the number has been rising.   The National Health Research Institute, the NHIA and the HPA jointly organize a two-day seminar on the precision treatments for cancers.  The seminar will be live-streamed.

Dr Liang Kung-Yi, the President of the NHRI, expressed that Taiwan has already embarked on the researches of precision medicine for treating cancers.  The Institute will formulate genetic testing program for some common cancers in Taiwan, such as lung cancer, breast cancer, and digestive tract cancer.  The NHRI will help hospitals to recruit cancer patients to participate in the program for the access to genetic tests, and possibly to targeted treatments, immunotherapies and clinical trials.  The objectives are to achieve the patient-centered care and to promote personalized treatment.

The genome data collected from patients in Taiwan will be used to create a data platform, which can be integrated into the electronic patient records.  The well-structured and integrated databank can provide further information for the industry.  Therefore, the HPA is keen in encouraging the industry to jointly promote the pharmaceutical R&D and the public’s health.

【2021-03-16 / United Daily 】